EX-99.1 2 ef20053560_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

Solventum Corporation
 
Unaudited Pro Forma Condensed Consolidated Financial Statements
  
On February 25, 2025, Solventum Corporation (“Solventum”, the “Company”) entered into a Transaction Agreement to sell its purification and filtration business to Thermo Fisher Scientific Inc. (“Buyer”) for $4.1 billion. On June 25, 2025, the Company and Buyer entered into an Amended and Restated Transaction Agreement to exclude the Company’s drinking water filtration business (the “Water Business”) from the scope of the purification and filtration business (the “Business”) to be acquired by Buyer and reduce the cash consideration at closing of the transaction to approximately $4.0 billion (the “Transaction”).
 
The unaudited pro forma condensed consolidated financial statements have been derived from the Company’s historical consolidated financial statements and give effect to the Transaction. The following unaudited pro forma condensed consolidated balance sheet as of June 30, 2025 reflects the Company’s financial position as if the Transaction had occurred on June 30, 2025. The following unaudited pro forma condensed consolidated statements of income for the six months ended June 30, 2025 and year ended December 31, 2024 reflect the Company’s results as if the Transaction had occurred as of January 1, 2024 for all periods presented.
 
The unaudited pro forma condensed consolidated financial statements have been prepared based upon the best available information and management estimates and are subject to assumptions and adjustments described below and in the accompanying notes to those financial statements. Management believes these assumptions and adjustments are reasonable, given the information available at the filing date. The unaudited pro forma condensed consolidated financial statements have been prepared in accordance with Regulation S-X Article 11. They are not intended to be a complete presentation of the Company’s financial position or results of operations had the Transaction occurred as of and for the periods indicated. In addition, the unaudited pro forma condensed consolidated financial statements are provided for illustrative and informational purposes only and are not necessarily indicative of the Company’s future results of operations or financial condition had the Transaction been completed on the dates assumed. The actual financial position and results of operations may differ significantly from the pro forma amounts reflected herein due to a variety of factors. The unaudited pro forma condensed consolidated financial statements should be read in conjunction with our historical consolidated financial statements and accompanying notes, specifically in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the “SEC”) on February 28th, 2025, and the Company’s Quarterly Report on Form 10-Q for the quarterly period ending June 30, 2025, as filed with the SEC on August 8, 2025.

1

Solventum Corporation
Unaudited Pro Forma Condensed Consolidated Balance Sheet*
(Dollars in millions, except per-share data)

   
As of June 30, 2025
 
   
Historical Solventum (as reported)
   
Disposal of Business (a)
   
Transaction Accounting Adjustments
     
Pro Forma
 
Assets
                         
Current assets
                         
Cash and cash equivalents
 
$
492
   
$
   
$
3,890
 
(b)
 
$
4,382
 
Accounts receivable — net of allowances of $87
   
1,065
     
     
       
1,065
 
Due from related parties
   
190
     
     
       
190
 
Inventories
                                 
Finished goods
   
553
     
     
       
553
 
Work in process
   
173
     
     
       
173
 
Raw materials and supplies
   
236
     
     
       
236
 
Total inventories
   
962
     
     
       
962
 
Other current assets
   
331
     
     
       
331
 
Current assets held for sale
   
168
     
(168
)
   
       
 
Total current assets
   
3,208
     
(168
)
   
3,890
       
6,930
 
Property, plant and equipment — net
   
1,313
     
     
       
1,313
 
Goodwill
   
5,274
     
     
       
5,274
 
Intangible assets — net
   
2,302
     
     
       
2,302
 
Other assets
   
917
     
     
       
917
 
Non-current assets held for sale
   
2,060
     
(1,962
)
   
       
98
 
Total assets
 
$
15,074
   
$
(2,130
)
 
$
3,890
     
$
16,834
 
Liabilities
                                 
Current liabilities
                                 
Accounts payable
 
$
643
   
$
   
$
     
$
643
 
Due to related parties
   
355
     
     
       
355
 
Unearned revenue
   
557
     
     
       
557
 
Other current liabilities
   
1,011
     
     
502
 
(d)(e)(g)
   
1,513
 
Current liabilities held for sale
   
54
     
44
     
       
98
 
Total current liabilities
   
2,620
     
44
     
502
       
3,166
 
Long-term debt
   
7,815
     
     
       
7,815
 
Pension and postretirement benefits
   
354
     
     
       
354
 
Deferred income taxes
   
231
     
     
(76
)
(f)
   
155
 
Other liabilities
   
371
     
     
118
 
(c)(g)
   
489
 
Non-current liabilities held for sale
   
38
     
(38
)
   
       
 
Total liabilities
 
$
11,429
   
$
6
   
$
544
     
$
11,979
 
                                   
Equity
                                 
Common stock par value, $0.01 par value, 750,000,000 shares authorized
 
$
2
   
$
   
$
     
$
2
 
Shares issued and outstanding - June 30, 2025: 173,387,361
                                 
Additional paid-in capital
   
3,806
     
     
       
3,806
 
Retained earnings
   
468
     
(2,136
)
   
3,346
 
(h)
   
1,678
 
Accumulated other comprehensive income (loss)
   
(631
)
   
     
       
(631
)
Total equity
   
3,645
     
(2,136
)
   
3,346
       
4,855
 
Total liabilities and equity
 
$
15,074
   
$
(2,130
)
 
$
3,890
     
$
16,834
 
*Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum.

2

Solventum Corporation
Unaudited Pro Forma Condensed Consolidated Statements of Income*
(Dollars in millions, except per-share data)

   
Six months ended June 30, 2025
 
   
Historical Solventum (as reported)
   
Disposal of Business (a)
   
Transaction Accounting Adjustments
     
Pro Forma
 
Net sales of product
 
$
3,265
   
$
(369
)
 
$
     
$
2,896
 
Net sales of software and rentals
   
966
     
     
       
966
 
Total net sales
   
4,231
     
(369
)
   
       
3,862
 
Cost of product
   
1,700
     
(191
)
   
       
1,509
 
Cost of software and rentals
   
242
     
     
       
242
 
Gross profit
   
2,289
     
(178
)
   
       
2,111
 
Selling, general and administrative expenses
   
1,541
     
(42
)
   
(63
)
(i)
   
1,436
 
Research and development expenses
   
381
     
(23
)
   
(5
)
(i)
   
353
 
Operating income
   
367
     
(113
)
   
68
       
322
 
Interest expense, net
   
207
     
     
2
 
(c)
   
209
 
Other expense (income), net
   
19
     
     
       
19
 
Income before income taxes
   
141
     
(113
)
   
66
       
94
 
Provision for (benefit from) income taxes
   
(86
)
   
(25
)
   
119
 
(j)
   
8
 
Net income
 
$
227
   
$
(88
)
 
$
(53
)
   
$
86
 
                                   
Earnings per share:
                                 
Basic earnings per share
 
$
1.31
                       
$
0.49
 
Diluted earnings per share
   
1.30
                       
0.49
 
Weighted-average number of shares outstanding:
                                 
Basic
   
173.9
                       
173.9
 
Diluted
   
175.0
                       
175.0
 
*Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum.

3

Solventum Corporation
Unaudited Pro Forma Condensed Consolidated Statements of Income (Continued)*
(Dollars in millions, except per-share data)

   
Year ended December 31, 2024
 
   
Historical Solventum (as reported)
   
Disposal of Business (a)
   
Transaction Accounting Adjustments
     
Pro Forma
 
Net sales of product
 
$
6,348
   
$
(709
)
 
$
     
$
5,639
 
Net sales of software and rentals
   
1,906
     
     
       
1,906
 
Total net sales
   
8,254
     
(709
)
   
       
7,545
 
Cost of product
   
3,172
     
(421
)
   
       
2,751
 
Cost of software and rentals
   
489
     
     
       
489
 
Gross profit
   
4,593
     
(288
)
   
       
4,305
 
Selling, general and administrative expenses
   
2,782
     
(86
)
   
(136
)
(i)
   
2,560
 
Research and development expenses
   
775
     
(44
)
   
(10
)
(i)
   
721
 
Gain on sale of business
   
     
     
1,564
  (k)
   
1,564
 
Operating income
   
1,036
     
(158
)
   
1,710
       
2,588
 
Interest expense, net
   
367
     
     
4
 
(c)
   
371
 
Other expense (income), net
   
64
     
     
       
64
 
Income before income taxes
   
605
     
(158
)
    1,706        
2,153
 
Provision for (benefit from) income taxes
   
127
     
(35
)
   
385
 
(d)(f)(j)
   
477
 
Net income
 
$
479
   
$
(123 )
 
$
1,321      
$
1,677
 
                                   
Earnings per share:
                                 
Basic earnings per share
 
$
2.77
                       
$
9.68
 
Diluted earnings per share
   
2.76
                       
9.65
 
Weighted-average number of shares outstanding:
                                 
Basic
   
173.2
                       
173.2
 
Diluted
   
173.7
                       
173.7
 
*Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum.

4

Notes to the Unaudited Pro Forma Condensed Consolidated Financial Statements
 
Disposal of Business
 

(a)
These adjustments reflect the removal of assets and liabilities that had been reported as “held for sale” as of June 30, 2025, as well as the removal of historical results of operations of the Business for the six months ended June 30, 2025 and the year ended December 31, 2024. The historical results of operations, which were removed, exclude general corporate overhead costs which were historically allocated to the Business. These allocations included labor and non-labor expenses related to the Company’s corporate support functions, such as those related to finance, accounting, tax, treasury, IT, HR, legal, and others.

Due to restrictions in certain jurisdictions, the transfer of both assets and employees in those jurisdictions will be delayed. Under various agreements between Buyer and the Company, the future economic benefits and obligations of the Business in these jurisdictions will transfer upon the closing of the Transaction. Consequently, approximately $98 million of non-current assets held for sale will remain after the close of the Transaction, and the Company will record a corresponding current liability reflecting the Company’s obligation to transfer the related assets to Buyer at a future date.
 
Transaction Accounting Adjustments
 

(b)
Reflects the expected cash consideration received from the sale of the Business at the close of the Transaction, adjusted for estimated transaction costs and other items pursuant to the terms of the sale. The final cash amount will be determined subsequent to closing based on the final working capital balance and final indebtedness as defined by the Transaction Agreement.

(Millions)
     
Purchase price
 
$
4,000
 
Transaction costs due at close
   
(72
)
Estimated net working capital adjustments
   
(4)
 
Estimated indebtedness at close
   
(34
)
Total closing cash consideration
 
$
3,890
 


(c)
Under the Transaction Agreement, Buyer will be entitled to receive a payment of up to $75 million from the Company either upon a sale of the Water Business or after an agreed upon 3-year period. The Company has estimated that the present value of this liability will be $64 million at the closing of the Transaction. Interest accretion will be recognized over a 3-year period from the date of the Transaction.


(d)
Reflects the estimated income taxes payable related to the Transaction of $430 million.


(e)
Reflects the estimated transfer taxes payable in certain foreign jurisdictions related to the Transaction of $20 million.


(f)
Reflects the net impact of deferred tax liability reversals associated with long-lived assets of $181 million and deferred tax asset reversals of $105 million related to the sale of shares in certain subsidiaries in connection with the Transaction.

5


(g)
Reflects the recognition of approximately $106 million of unfavorable contract liabilities relating to certain transition services to be provided by the Company, of which $52 million is included in other current liabilities and $54 million is included in other non-current liabilities. Under the transition service agreements, the Company will provide to Buyer services at a cost, below fair market value. Consequently, a portion of the sale consideration received has been allocated to these services which management expects will be fulfilled by the Company over a 24-month term.


(h)
Reflects the effect on total equity of the adjustments described in notes (b) through (g) above.


(i)
In connection with the sale, the Company and Buyer will enter into transition services, transition contract manufacturing, transition distribution services, and various other agreements whereby the Company will provide certain post-closing services on a transitional basis. The estimated impacts of these agreements have been reflected within selling, general and administrative expenses or research and development expenses, depending on the nature of the services provided. The majority of these agreements have an initial term of 24 months following the close of the Transaction.

The transition service income has been presented net of estimated incremental information technology costs not included in the historical financial statements of approximately $20 million and $40 million for the six months ended June 30, 2025 and the year ended December 31, 2024, respectively. The costs represent information technology services that the Company has agreed to provide to support Buyer’s information technology separation.


(j)
Reflects the tax impact of pro forma adjustments relating to the removal of the Business, as well as the estimated tax impact attributable to the various transition services provided by the Company. This adjustment was determined by applying the relevant statutory tax rates to the jurisdictional mix of income of these adjustments. For the six months ended June 30, 2025, the transaction accounting adjustment also reflects the impact of deferred tax asset reversals of $105 million related to the sale of shares in certain subsidiaries in connection with the Transaction.


(k)
The estimated pre-tax gain on the sale of the Business, as reflected in the condensed consolidated statement of income for the year ended December 31, 2024, is calculated as follows:
 
(Millions)
     
Total closing cash consideration (b)
 
$
3,890
 
Net assets of the Business
   
(2,136
)
Transaction accounting adjustments (c)(e)(g)
   
(190
)
Pre-tax gain on sale of business
 
$
1,564
 
 
The estimated income taxes due on the gain of the sale of $430 million and the net impact of deferred tax liability reversals of $76 million are reflected in the provision for (benefit from) income taxes in the condensed consolidated statement of income for the year ended December 31, 2024.

6